Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Quarterly Earnings Results, Beats Estimates By $4.13 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN) announced its earnings results on Thursday. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13, FiscalAI reports. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the business posted $12.81 earnings per share.

Here are the key takeaways from Regeneron Pharmaceuticals’ conference call:

• Strong second-quarter performance: Total revenue rose 17% year over year to $4.3 billion, while non-GAAP EPS increased 11% to $14.29. Dupixent, EYLEA HD, and Libtayo each reached record quarterly sales.
• Dupixent momentum remains robust, with global sales of $6 billion, up 38% at constant exchange rates, supported by growth across existing indications and newer launches. Growth is expected to remain strong, though it will moderate in the second half due to tougher comparisons.
• EYLEA HD is rapidly converting the U.S. franchise: sales increased 52% year over year to $596 million and exceeded legacy EYLEA sales for the first time. Regeneron is pursuing approval of a pre-filled syringe, which management believes could further improve adoption.
• Several pipeline catalysts are approaching, including potential FDA decisions for cemdisiran in generalized myasthenia gravis in November and garetosmab in FOP in August, along with data readouts for the PNH complement program and geographic atrophy program later this year.
• Legacy EYLEA remains under pressure: U.S. sales fell 45% year over year to $412 million as patients converted to EYLEA HD and competition increased. Management expects further low-to-mid-teens sequential demand declines in the second half, partly because of multiple aflibercept biosimilar launches.

Regeneron Pharmaceuticals Trading Down 0.3%

NASDAQ REGN traded down $2.13 on Friday, hitting $736.21. 154,832 shares of the company were exchanged, compared to its average volume of 854,341. The company’s 50 day moving average price is $640.66 and its 200-day moving average price is $711.35. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The firm has a market capitalization of $77.83 billion, a P/E ratio of 18.00, a price-to-earnings-growth ratio of 27.78 and a beta of 0.24. Regeneron Pharmaceuticals has a twelve month low of $541.00 and a twelve month high of $821.11.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Analyst Ratings Changes

A number of brokerages have weighed in on REGN. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a report on Tuesday, July 7th. HSBC cut their target price on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Sanford C. Bernstein reduced their target price on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Finally, Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $790.08.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Large investors have recently made changes to their positions in the company. Dodge & Cox boosted its stake in Regeneron Pharmaceuticals by 1.0% in the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock worth $3,547,791,000 after purchasing an additional 45,513 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares during the period. Invesco Ltd. raised its stake in Regeneron Pharmaceuticals by 38.0% during the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after purchasing an additional 408,649 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 38.0% in the fourth quarter. AQR Capital Management LLC now owns 995,710 shares of the biopharmaceutical company’s stock valued at $768,518,000 after purchasing an additional 274,356 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 2.7% in the third quarter. Northern Trust Corp now owns 984,792 shares of the biopharmaceutical company’s stock valued at $553,719,000 after purchasing an additional 26,223 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong Q2 results: Regeneron reported non-GAAP earnings of $14.29 per share, well above the approximately $10.16 consensus estimate, while revenue rose 16.7% year over year to $4.29 billion, surpassing expectations. Regeneron Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Core products delivered powerful growth: Dupixent sales, recorded by partner Sanofi, increased 38% to a record $6.0 billion, while U.S. EYLEA HD sales jumped 52% to a record $596 million. Libtayo sales also rose 30% to $489 million, helping offset declines in the original EYLEA franchise. Regeneron beats quarterly estimates on eczema drug strength, shares rise
• Positive Sentiment: Additional shareholder return and pipeline support: The company declared a quarterly dividend of $0.94 per share. Investors are also watching potential long-term growth from investigational food-allergy therapies and a collaboration with Telix Pharmaceuticals to develop radiopharmaceutical oncology treatments.
• Neutral Sentiment: Valuation remains debated: Despite a roughly 36% gain over the past year and a trailing price-to-earnings ratio near 18, analysts characterize REGN as neither an obvious bargain nor clearly overvalued, leaving future pipeline execution and earnings growth central to the outlook. Regeneron Stock Looks Cheap On Earnings Yet Mixed Elsewhere
• Negative Sentiment: Clinical and legal overhang: Regeneron’s Phase 3 Fianlimab-Libtayo trial in advanced melanoma failed, prompting allegations that investors were misled about the study’s risks and protocol changes. Multiple law firms have announced or promoted securities class actions, citing the prior market-value loss. The litigation could increase reputational, financial and investor-confidence risks, although the announcements themselves do not represent findings of wrongdoing. Hagens Berman Regeneron investor alert

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.